Meyer, Braydon
Clifton, Samuel
Locke, Warwick
Luu, Phuc-Loi
Du, Qian
Lam, Dilys
Armstrong, Nicola J.
Kumar, Beena
Deng, Niantao
Harvey, Kate
Swarbrick, Alex
Ganju, Vinod
Clark, Susan J.
Pidsley, Ruth
Stirzaker, Clare http://orcid.org/0000-0001-5601-3140
Funding for this research was provided by:
National Health and Medical Research Council (1106870, 1063559, 1156408)
National Breast Cancer Foundation (IIRS-18-137)
Cancer Council NSW (RG-18-09)
National Foundation for Medical Research and Innovation
Article History
Received: 24 September 2021
Accepted: 7 December 2021
First Online: 18 December 2021
Declarations
:
: The SETUP study tumour samples were obtained from Monash and Peninsula Health (Melbourne, Australia). Patients with locally advanced breast cancer, deemed suitable for neoadjuvant cytotoxic chemotherapy, consented for the collection of imaging data and biological specimens for biomarker analysis (SETUP study) and were enrolled in a phase III randomised controlled neoadjuvant clinical trial approved by the Human Ethics Research Committee and the Monash Medical Centre (ANZCTR.org.au clinical trials identifier: ACTRN12605000588695; HREC/SETUP/03169A0).
: Not applicable.
: The authors declare that they have no competing interests.